NCT05612789 Improve Outcomes for Older Allogeneic Transplant Recipients
| NCT ID | NCT05612789 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Condition | Allogeneic Transplantation |
| Study Type | INTERVENTIONAL |
| Enrollment | 72 participants |
| Start Date | 2023-02-15 |
| Primary Completion | 2030-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 72 participants in total. It began in 2023-02-15 with a primary completion date of 2030-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an interventional pilot study to determine whether implementation of a supervised exercise program can improve outcomes in subjects undergoing allogeneic HCT. The primary objective is to determine feasibility. Up to 60-72 evaluable subjects will be enrolled. Evaluable subjects are defined as those participating in the exercise intervention.
Eligibility Criteria
Inclusion Criteria: Cohort A (Prehab) 1. Age 60 years or older. 2. Planned allogeneic HCT in the next 1-6 months. 3. Hematological malignancy as the indication for HCT. 4. Pre-frail or frail by Fried frailty phenotype. Cohort B (Rehab) 1. Age 60 years or older. 2. Planned allogeneic HCT or HCT within the last 30 days. 3. Hematological malignancy as the indication for HCT. Exclusion Criteria: Cohorts A and B 1\. Comorbid disability or illness that prevents safe exercise.
Contact & Investigator
Shannon McCurdy, MD
PRINCIPAL INVESTIGATOR
Penn Medicine
Frequently Asked Questions
Who can join the NCT05612789 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, studying Allogeneic Transplantation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05612789 currently recruiting?
Yes, NCT05612789 is actively recruiting participants. Contact the research team at Jacqui.Rick@pennmedicine.upenn.edu for enrollment information.
Where is the NCT05612789 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT05612789 clinical trial?
NCT05612789 is sponsored by Abramson Cancer Center at Penn Medicine. The principal investigator is Shannon McCurdy, MD at Penn Medicine. The trial plans to enroll 72 participants.